Expanded Collaboration to Improve Syndromic Infectious Disease TestingMISSISSAUGA, Ontario and IRVINE, Calif., Dec. 14, 2023 Microbix Biosystems Inc. , a life sciences innovator, manufacturer,.
Share:
MISSISSAUGA, Ontario and TORONTO, March 15, 2021 (GLOBE NEWSWIRE) Microbix Biosystems Inc. (TSX:MBX, OTCQB:MBXBF, Microbix®)), a life sciences innovator and exporter, and Seegene Canada Inc. (Seegene®), a provider of leading-edge molecular diagnostics assays and instruments (made by Seegene Inc. of Seoul, Korea), are pleased to announce a collaboration under which Seegene will distribute and recommend Microbix s new COVID-variant Quality Assessment Products (QAPs™) to monitor the workflow accuracy of Seegene Allplex® assays across Canada.
In this collaboration, Seegene becomes a QAPs distributor and will recommend Microbix s whole-genome COVID-variant QAPs to support Seegene s molecular assays that detect the more-contagious emerging strains of the SARS-CoV-2 virus – initially the Brazilian, South African, & UK variants (P.1, B.1.351, & B1.1.7 respectively). Seegene s unique Allplex assays more rapidly and economically detect the genetic point-mutations associated